While reduced SHBG increases the fraction of bioavailable estradiol and testosterone, increasing risk for hormone-responsive tumors; elevated IGF-1 could stimulate the growth of breast cancer cells in absence of ER or PR activation [47–49]. Here, IGF1 is linked to breast carcinoma.